Evaluation of Different Approaches in Managing Local Skin Reactions With the Use of Ingenol Mebutate 0.015% and 0.05% During the Treatment of Actinic Keratosis

Main Article Content

Scott Freeman
Miriam Bettencourt
Meg Corliss
Nikeshia Dunkelly-Allen
Karen A Veverka


Actinic Keratosis, Ingenol Mebutate, topical, Local skin reaction, management


Abstract not available.


1. Berman B, Cohen DE, Amini S. What is the role of field-directed therapy in the treatment of actinic keratosis? Part 1: Overview and investigational topical agents. Cutis. 2012;89(5):241-250.

2. Bettencourt MS. Tolerability of ingenol mebutate gel, 0.05%, for treating patients with actinic keratosis on the scalp in a community dermatology practice. J Clin Aesthet Dermatol. 2016;9(3):20-24.

3. Picato (ingenol mebutate) gel 0.015%, 0.05% [package insert]. Madison, NJ: LEO Pharma Inc.; 2019.

4. Lebwohl M, Swanson N, Anderson LL, et al. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366(11):1010-1019.

5. Hanke WC, Norlin JM, Mark Knudsen K, et al. Quality of life in treatment of AK: treatment burden of ingenol mebutate gel is small and short lasting. J Dermatolog Treat. 2016;27(5):450-455.

6. Joe HJ, Oh BH. Ingenol mebutate in low amounts for the treatment of actinic keratosis in Korean patients. Clin Cosmet Investig Dermatol. 2017;10:93-98.

7. Bettencourt MS. Use of ingenol mebutate gel for actinic keratosis in patients in a community dermatology practice. J Drugs Dermatol. 2014;13(3):269-273.

8. Erlendsson AM, Karmisholt KE, Haak CS, et al. Topical corticosteroid has no influence on inflammation or efficacy after ingenol mebutate treatment of grade I to III actinic keratoses (AK): a randomized clinical trial. J Am Acad Dermatol. 2016;74(4):709-715.

9. Jim On SC, Hashim PW, Nia JK, Lebwohl MG. Assessment of efficacy and irritation of ingenol mebutate gel 0.015% used with or without dimethicone lotion for treatment of actinic keratosis on the face. J Drugs Dermatol. 2017;16(5):432-436.

10. Neri L, Peris K, Longo C, et al; Actinic Keratosis — TReatment Adherence INitiative (AK-TRAIN) study group. Physician-patient communication and patient-reported outcomes in the actinic keratosis treatment adherence initiative (AK-TRAIN): a multicenter, prospective, real-life study of treatment satisfaction, quality of life and adherence to topical field-directed therapy for the treatment of actinic keratosis in Italy. J Eur Acad Dermatol Venereol. 2019;33(1):93-107.

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)